News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
589,937 Results
Type
Article (21030)
Company Profile (360)
Press Release (568540)
Multimedia
Podcasts (132)
Webinars (16)
Section
Business (194526)
Career Advice (436)
Deals (29934)
Drug Delivery (73)
Drug Development (71443)
Employer Resources (40)
FDA (12298)
Job Trends (10579)
News (285432)
Policy (22194)
Tag
2025 Best Places to Work (17)
2026 Best Places to Work (26)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (7)
2027 Biotech Beach Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (5)
2027 Pharm Country Standard (3)
40 Under 40 (4)
Academia (1269)
Accelerated approval (53)
ADA (39)
Adcomms (16)
Allergies (160)
Alliances (41170)
ALS (245)
Alzheimer's disease (1583)
Antibody-drug conjugate (ADC) (672)
Approvals (13035)
Artificial intelligence (696)
ASCO (274)
Autoimmune disease (457)
Automation (44)
Bankruptcy (304)
Belgium (30)
Best Places to Work (8506)
BIO (67)
Biologics (90)
BIOSECURE Act (6)
Biosimilars (204)
BioSpace Insights (92)
Biotechnology (228)
Bispecific (60)
Bladder cancer (195)
Brain cancer (77)
Breast cancer (762)
Cancer (6421)
Cardiovascular disease (466)
Career advice (385)
Career pathing (16)
CAR-T (378)
CDC (11)
CDMO (143)
Celiac Disease (6)
Cell therapy (1013)
Cervical cancer (50)
Clinical research (64744)
Collaboration (2291)
Commercialization (60)
Company closure (4)
Compensation (1783)
Complete response letters (81)
COVID-19 (1470)
CRISPR (140)
CRO (4)
C-suite (1360)
Cystic fibrosis (152)
Data (9548)
Denatured (30)
Depression (173)
Dermatology (167)
Diabetes (564)
Diagnostics (4971)
Digital health (52)
Diversity (6)
Diversity, equity & inclusion (12)
Drug discovery (405)
Drug pricing (61)
Drug shortages (6)
Duchenne muscular dystrophy (382)
Earnings (81690)
Editorial (39)
Employer branding (6)
Employer resources (38)
ESMO (384)
Events (105501)
Executive appointments (1062)
Eye disease (18)
FDA (16350)
Fibrodysplasia Ossificans Progressiva (15)
Fragile X (6)
Friedreich's ataxia (29)
Frontotemporal dementia (39)
Funding (1860)
Gene editing (285)
Generative AI (53)
Gene therapy (820)
GLP-1 (753)
Government (1790)
Grass and pollen (4)
Guidances (343)
Healthcare (12211)
Hematology (180)
HIV (81)
Huntington's disease (78)
Idiopathic pulmonary fibrosis (11)
IgA nephropathy (130)
Immunology and inflammation (314)
Immuno-oncology (135)
Indications (259)
Infectious disease (1758)
Inflammatory bowel disease (235)
Inflation Reduction Act (12)
Influenza (101)
Intellectual property (345)
Interviews (58)
IPO (14398)
IRA (13)
Job creations (2424)
Job search strategy (341)
JPM (41)
Kidney cancer (23)
Kidney disease (149)
Labor market (46)
Layoffs (320)
Leadership (22)
Legal (5652)
Licensing (120)
Liver cancer (72)
Longevity (47)
Lung cancer (910)
Lung diease (19)
Lymphoma (452)
Machine learning (50)
Management (10)
Manufacturing (1006)
Marketing (36)
MASH (209)
Medical affairs (5)
Medical device (9998)
Medtech (10226)
Melanoma (119)
Mergers & acquisitions (16874)
Metabolic disorders (1403)
Middle East (1)
mRNA (244)
Multiple sclerosis (188)
Multispecific (7)
NASH (14)
Netherlands (20)
Neurodegenerative disease (505)
Neuropsychiatric disorders (115)
Neuroscience (3340)
Neurotech (3)
NextGen: Class of 2026 (4136)
Non-profit (1529)
Now hiring (50)
Obesity (588)
Opinion (167)
Ovarian cancer (262)
Pain (269)
Pancreatic cancer (383)
Parkinson's disease (411)
Partnered (26)
Patents (674)
Patient advocacy (8)
Patient recruitment (846)
Patient selection (102)
Peanut (61)
People (50147)
Peptides (37)
Pharmaceutical (51)
Pharmacy benefit managers (16)
Phase 1 (21379)
Phase 2 (29236)
Phase 3 (19901)
Pipeline (12288)
Policy (124)
Postmarket research (1893)
Preclinical (9127)
Press Release (52)
Prostate cancer (331)
Psychedelics (92)
Radioligand (3)
Radiopharmaceuticals (389)
Rare diseases (1270)
Real estate (3789)
Recruiting (14)
Regenerative medicine (29)
Regulatory (20186)
Reports (43)
Research institute (1350)
Resumes & cover letters (59)
Rett syndrome (58)
RNA editing (38)
RSV (61)
Schizophrenia (194)
Series A (348)
Series B (241)
Series C (1)
Service/supplier (5)
Sickle cell disease (131)
Special edition (24)
Spinal muscular atrophy (150)
Sponsored (25)
Startups (3138)
State (1)
Stem cells (7)
Stomach cancer (10)
Substance use disorders (22)
Supply chain (84)
Switzerland (15)
Tariffs (21)
The Weekly (100)
Vaccines (639)
Venture capital (128)
Weight loss (302)
Wet AMD (6)
Women's health (132)
Women in leadership (1)
Worklife (4)
Date
Today (94)
Last 7 days (581)
Last 30 days (3237)
Last 365 days (26279)
2026 (24106)
2025 (25773)
2024 (30049)
2023 (34003)
2022 (43335)
2021 (45752)
2020 (40912)
2019 (29877)
2018 (22497)
2017 (24201)
2016 (22686)
2015 (28880)
2014 (24880)
2013 (20689)
2012 (22503)
2011 (22757)
2010 (22437)
Location
Africa (344)
Alabama (101)
Alaska (3)
Arizona (378)
Arkansas (15)
Asia (29444)
Australia (4542)
California (15513)
Canada (4141)
China (1575)
Colorado (653)
Connecticut (609)
Delaware (420)
Europe (54903)
Florida (2263)
Georgia (465)
Hawaii (4)
Idaho (47)
Illinois (1070)
India (109)
Indiana (484)
Iowa (25)
Japan (650)
Kansas (122)
Kentucky (42)
Louisiana (46)
Maine (38)
Maryland (1611)
Massachusetts (11163)
Michigan (342)
Minnesota (707)
Mississippi (6)
Missouri (102)
Montana (32)
Nebraska (14)
Nevada (164)
New Hampshire (76)
New Jersey (3629)
New Mexico (19)
New York (3789)
North Carolina (1868)
North Dakota (11)
Northern California (8064)
Ohio (385)
Oklahoma (16)
Oregon (37)
Pennsylvania (2991)
Puerto Rico (28)
Rhode Island (43)
South America (528)
South Carolina (87)
South Dakota (1)
Southern California (6220)
Tennessee (165)
Texas (2519)
United States (52225)
Utah (456)
Vermont (1)
Virginia (277)
Washington D.C. (52)
Washington State (1228)
West Virginia (2)
Wisconsin (127)
Wyoming (2)
589,937 Results for "dmd therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Precision BioSciences Announces Positive DSMB Safety Review Supporting Additional PBGENE-DMD Dosing in Phase 1/2 FUNCTION-DMD Study
November 5, 2026
·
10 min read
Manufacturing
Capricor ramps up manufacturing spend ahead of FDA decision for DMD therapy
Less than two weeks away from a highly anticipated FDA ruling on its cell therapy for Duchenne muscular dystrophy, Capricor Therapeutics has reported increased investment in its San Diego plant to support commercial production.
November 11, 2026
·
2 min read
·
Nick Paul Taylor
Earnings
Sarepta’s new CEO confident in clinical execution as DMD competitors close in
Sarepta Therapeutics’ newly minted CEO Michael Severino laid out his path to returning the muscular dystrophy therapy maker to the forefront of the rapidly expanding market.
November 6, 2026
·
6 min read
·
Annalee Armstrong
Press Releases
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
September 28, 2026
·
5 min read
Layoffs
Capricor parts ways with 10% of staff as FDA decision on DMD cell therapy nears
Awaiting a decision on Nov. 22 for its embattled Duchenne muscular dystrophy cell therapy deramiocel, Capricor has reduced its workforce by 10% and slowed programs not directly related to deramiocel, the biotech revealed in its third quarter earnings report.
November 11, 2026
·
3 min read
·
Heather McKenzie
Opinion
FDA’s rare disease framework faces its first real test in Capricor’s DMD drug
Last month, the FDA committed to designing a “fit-for-purpose” framework for regulating rare disease therapies based on patient need and realistically attainable evidence. With the upcoming decision for Capricor’s Duchenne muscular dystrophy cell therapy deramiocel, this paradigm faces its first key test.
November 10, 2026
·
4 min read
·
Elijah Stacy
Press Releases
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting
September 3, 2026
·
5 min read
Press Releases
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45
October 14, 2026
·
11 min read
Press Releases
Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study
August 24, 2026
·
11 min read
FDA
Capricor’s DMD therapy still alive, Merck/Moderna’s cancer vax shines, FDA’s future revealed
FDA extends its review of Capricor Therapeutics’ Duchenne muscular dystrophy cell therapy as an unhappy shareholder advocates for change; Merck and Moderna tout positive data for their mRNA-based cancer vaccine; Trump nominates White House aide Heidi Overton as FDA commissioner; and the oral obesity market heats up with rivals Eli Lilly and Novo Nordisk going head-to-head.
August 26, 2026
·
2 min read
·
Jef Akst
1 of 58,994
Next